This review synthesizes contemporary evidence to: (1) define evidence-based prenatal ultrasound criteria for Apert syndrome, incorporating recent advances in 3D imaging; (2) establish the complementary roles of MRI and FGFR2 sequencing within a stratified diagnostic pathway; (3) analyze the impact of early diagnosis on multidisciplinary care coordination, with an emphasis on perinatal airway management; and (4) discuss emerging molecular therapies (e.g., MEK inhibitors) transitioning from preclinical models to clinical trials. Here, FGFR2 is linked to Apert syndrome.